Clostridium difficile: new therapeutic options

Current Opinion in Pharmacology

Volumn 7, Issue 5, 2007, Pages 455-458

  Balagopal, Ashwin ^a   Sears, Cynthia L ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDIARRHEAL AGENT; CLINDAMYCIN; IMMUNOGLOBULIN; METRONIDAZOLE; NITAZOXANIDE; OLIGOFRUCTOSE; PLACEBO; PREBIOTIC AGENT; PROBIOTIC AGENT; RAMOPLANIN; RIFAMPICIN; RIFAXIMIN; TOLEVAMER; TOXOID; UNCLASSIFIED DRUG; VANCOMYCIN;

BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DIARRHEA; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPIDEMIC; FEASIBILITY STUDY; HOSPITAL INFECTION; HUMAN; HYPOKALEMIA; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORBIDITY; NONHUMAN; PRIORITY JOURNAL; RECURRENT INFECTION; REVIEW; TRAVELLER DIARRHEA; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DEPSIPEPTIDES; DIARRHEA; HUMANS; POLYMERS; RIFAMPIN; THIAZOLES;

EID: 35248851268     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.05.007     Document Type: Review

References (30)

1. Surowiec D., Kuyumjian A.G., Wynd M.A., and Cicogna C.E. Past, present, and future therapies for Clostridium difficile-associated disease. Ann Pharmacother 40 (2006) 2155-2163
2. McDonald L.C., Killgore G.E., Thompson A., Owens Jr. R.C., Kazakova S.V., Sambol S.P., Johnson S., and Gerding D.N. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 (2005) 2433-2441. The investigators evaluated 187 isolates of C. difficile from eight health care facilities by pulsed-field electrophoresis, describing the BI/NAP1 isolate, its putative virulence mechanisms, and association with epidemic CDAD.
3. Severe Clostridium difficile-associated disease in populations previously at low risk - four states, 2005. MMWR Morb Mortal Wkly Rep 2005, 54:1201-1205.
4. Dial S., Delaney J.A., Barkun A.N., and Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 294 (2005) 2989-2995
5. Lowe D.O., Mamdani M.M., Kopp A., Low D.E., and Juurlink D.N. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 43 (2006) 1272-1276
6. Dial S., Delaney J.A., Schneider V., and Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 175 (2006) 745-748
7. Loo V.G., Poirier L., Miller M.A., Oughton M., Libman M.D., Michaud S., Bourgault A.M., Nguyen T., Frenette C., Kelly M., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 (2005) 2442-2449. A prospective study characterizing a Canadian outbreak (1703 patients) of CDAD associated with a high mortality because of the BI/NAP1 strain.
8. Bartlett J.G. New drugs for Clostridium difficile infection. Clin Infect Dis 43 (2006) 428-431. The author presents a review and editorial of recent therapeutics for CDAD, centered on nitazoxanide and tolevamer.
9. Pepin J., Alary M.E., Valiquette L., Raiche E., Ruel J., Fulop K., Godin D., and Bourassa C. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 40 (2005) 1591-1597. The authors performed a retrospective review of 845 patients from one Canadian hospital with CDAD treated with metronidazole and found that rates of recurrence in 2003-2004 had more than doubled compared with 1991-2002.
10. Aslam S., Hamill R.J., and Musher D.M. Treatment of Clostridium difficile-associated disease: old therapies and new strategies. Lancet Infect Dis 5 (2005) 549-557. The authors present a review of the history of CDAD and its treatment, the evolution of recurrent disease, and several of the newer agents which are under investigation.
11. Gerding D.N. New definitions will help, but cultures are critical for resolving unanswered questions about Clostridium difficile. Infect Control Hosp Epidemiol 28 (2007) 113-115
12. Modena S., Gollamudi S., and Friedenberg F. Continuation of antibiotics is associated with failure of metronidazole for Clostridium difficile-associated diarrhea. J Clin Gastroenterol 40 (2006) 49-54. The investigators performed an observational prospective study of 27 patients and found that patients who had 'offending' antibiotics discontinued all had improvement of their diarrhea, compared to improvement in only 59% of patients who had antibiotics continued.
13. Lamontagne F., Labbe A.C., Haeck O., Lesur O., Lalancette M., Patino C., Leblanc M., Laverdiere M., and Pepin J. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 245 (2007) 267-272. The authors conducted this retrospective review of 165 patients with CDAD requiring ICU care from 2 tertiary care hospitals in Quebec, Canada, and found that select patients were less likely to die if an emergency colectomy was performed.
14. Musher D.M., Aslam S., Logan N., Nallacheru S., Bhaila I., Borchert F., and Hamill R.J. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 (2005) 1586-1590. The authors prospectively observed 207 patients with CDAD in a Veterans' Hospital who were treated with metronidazole and reported that 28% of patients had a recurrence of CDAD within 90 days.
15. Pelaez T., Alcala L., Alonso R., Rodriguez-Creixems M., Garcia-Lechuz J.M., and Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46 (2002) 1647-1650
16. Musher D.M., Logan N., Hamill R.J., DuPont H.L., Lentnek A., Gupta A., and Rossignol J.F. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 43 (2006) 421-427. The investigators performed a double-blinded, prospective, randomized-controlled trial of nitazoxanide versus metronidazole for CDAD and found them to have similar rates of sustained response to therapy.
17. Young J.D., Mangino J.E., Stevenson K.B., and Koletar S.L. Nitazoxanide versus metronidazole for Clostridium difficile-associated colitis. Clin Infect Dis 44 (2007) 152-154
18. Lagrotteria D., Holmes S., Smieja M., Smaill F., and Lee C. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 43 (2006) 547-552
19. Louie T.J., Peppe J., Watt C.K., Johnson D., Mohammed R., Dow G., Weiss K., Simon S., John Jr. J.F., Garber G., et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 43 (2006) 411-420. The investigators conducted a prospective randomized-controlled double-blinded Phase II trial of tolevamer in patients with mild to moderately severe CDAD compared with vancomycin demonstrating noninferiority of vancomycin and higher dose tolevamer.
20. Fulco P., and Wenzel R.P. Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti-Infect Ther 4 (2006) 939-945
21. Aas J., Gessert C.E., and Bakken J.S. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36 (2003) 580-585
22. Dendukuri N., and Brophy J. Inappropriate use of meta-analysis to estimate efficacy of probiotics. Am J Gastroenterol 102 (2007) 201-204
23. McFarland L.V. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 101 (2006) 812-822
24. Louie T.J. Treatment of first recurrences of Clostridium difficile-associated disease: waiting for new treatment options. Clin Infect Dis 42 (2006) 765-767
25. Pepin J., Routhier S., Gagnon S., and Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec. Can Clin Infect Dis 42 (2006) 758-764
26. McFarland L.V., Elmer G.W., and Surawicz C.M. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 97 (2002) 1769-1775
27. Lewis S., Burmeister S., and Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol 3 (2005) 442-448
28. Enache-Angoulvant A., and Hennequin C. Invasive Saccharomyces infection: a comprehensive review. Clin Infect Dis 41 (2005) 1559-1568
29. Sougioultzis S., Kyne L., Drudy D., Keates S., Maroo S., Pothoulakis C., Giannasca P.J., Lee C.K., Warny M., Monath T.P., et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 128 (2005) 764-770
30. Johnson S., Schriever C., Galang M., Kelly C.P., and Gerding D.N. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 44 (2007) 846-848